Eli Lilly Withdraws COVID-19 Treatments from EMA Review
EMA has ended rolling review of bamlanivimab and etesevimab COVID-19 antibody treatments after Eli Lilly Netherlands BV withdraws from the review process.
The European Medicines Agency announced on Nov. 2, 2021 that it was stopping its rolling review of bamlanivimab and etesevimab COVID-19 antibody treatments after Eli Lilly Netherlands BV decided to remove the treatments from the review process. EMA’s Committee for Medicinal Products for Human Use (CHMP) had been reviewing data on the two products as part of the rolling review since March 2021. According to EMA, there were questions about the quality of the treatments.
In a letter from Lilly to EMA, the company stated that “CHMP has determined that prospective concurrent validation is required for submission of a formal marketing authorisation application. Given the current demand from EU member states, Lilly forecasts that no additional/new drug substance manufacturing campaigns will be needed for the foreseeable future. Therefore, at this point Lilly is not in a position to generate the additional data required by the CHMP to progress to a formal marketing authorization application.”
EMA stated in a press release that Lilly may request another rolling review or submit an application for market authorization in the future. “The withdrawal has no consequences on the previous advice issued in March and patients may continue to receive the medicines based on national arrangements,” the agency stated in the release.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
